ZONTIVITY Drug Patent Profile

Which patents cover Zontivity, and when can generic versions of Zontivity launch?

Zontivity is a drug marketed by Key Therap and is included in one NDA. There is one patent protecting this drug.

The generic ingredient in ZONTIVITY is vorapaxar sulfate. Additional details are available on the vorapaxar sulfate profile page.

DrugPatentWatch^® Generic Entry Outlook for Zontivity

Zontivity was eligible for patent challenges on May 8, 2018.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 23, 2027. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for ZONTIVITY

US Patents:	1
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for ZONTIVITY

ZONTIVITY is protected by one US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Key Therap	ZONTIVITY	vorapaxar sulfate	TABLET;ORAL	204886-001	May 8, 2014		DISCN	Yes	No			Y	Y

International Patents for ZONTIVITY

See the table below for patents covering ZONTIVITY around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	028952	ANTAGONISTAS RECEPTORES DE TROMBINA
Argentina	039570	ANTAGONISTAS DE LOS RECEPTORES DE TROMBINA
Argentina	045809	ANTAGONISTAS DEL RECEPTOR DE TROMBINA
Argentina	047088	POLIMORFO CRISTALINO DE PIRIDINETILENNAFTOFURANO COMO ANTAGONISTA DEL RECEPTOR DE TROMBINA, METODO DE OBTENCION Y COMPOSICIONES FARMACEUTICAS

Supplementary Protection Certificates for ZONTIVITY

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1495018	122015000053	Germany		PRODUCT NAME: VORAPAXAR ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ ODER SOLVAT DAVON; REGISTRATION NO/DATE: EU/1/14/976/001-006 20150119
1495018	2015C/037	Belgium		PRODUCT NAME: VORAPAXAR, OU SON SEL OU SOLVAT PHARMACOLOGIQUEMENT ADMISSIBLE; AUTHORISATION NUMBER AND DATE: EU/1/14/976/001
1495018	1590037-6	Sweden		PRODUCT NAME: VORAPAXAR, OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF; REG. NO/DATE: EU/1/14/976/001 20150121
1495018	300746	Netherlands		PRODUCT NAME: VORAPAXAR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF SOLVAAT, IN HET BIJZONDER VORAPAXARSULFAAT; REGISTRATION NO/DATE: EU/1/14/976/001-006 20150121

Summary

Last updated: February 3, 2026

ZONTIVITY (vorapaxar) is an antiplatelet agent developed by Merck (Keytruda developer). It inhibits thrombin receptor activity (PAR-1), aiming to reduce thrombotic cardiovascular events. Marketed for secondary prevention of myocardial infarction and artery thrombosis, ZONTIVITY's commercial success faces competition and regulatory challenges. The drug’s growth prospects depend on its clinical positioning, pricing, and evolving cardiovascular treatment guidelines.

Product Overview and Mechanism

ZONTIVITY is a reversible inhibitor of protease-activated receptor-1 (PAR-1). By blocking thrombin-mediated platelet activation, it reduces the incidence of thrombotic events in secondary prevention settings. The drug received FDA approval in 2014.

Regulatory and Market Status

• Approved indications target secondary prevention after myocardial infarction (MI) and established cardiovascular disease (CVD).
• Sales peaked around $170 million in 2016.
• Merck scaled back commercialization efforts afterward, citing limited market uptake.
• In 2020, Merck transferred rights to ZONTIVITY to privately held industry partners, limiting direct influence on sales.

Clinical Data and Efficacy

• Major trials: TRA 2°P-TIMI 50 demonstrated ZONTIVITY's capability to lower thrombotic events.
• Efficacy evidence shows modest benefits in reducing composite cardiovascular endpoints.
• No significant mortality benefit observed in trials.

Safety Profile

• Increased bleeding risk, a common class effect, limits broader usage.
• FDA labeling emphasizes caution in patients with active bleeding or high bleeding risk.

Competitive Landscape and Market Dynamics

Competitor / Drug	Class / Mechanism	Market Position	Commercial Outcome	Comments
Plavix (clopidogrel)	ADP receptor inhibitor	Dominant antiplatelet	$7.4B global in 2021	Extensive use, off-label combinations
Brilinta (ticagrelor)	P2Y12 inhibitor	Strong second line	$3.5B 2021	Better efficacy but higher bleeding
Vorapaxar (ZONTIVITY)	PAR-1 inhibitor	Niche / supplemental	Limited, ~$170M peak	Limited adoption, market share small

Market Challenges

• Narrow indication scope: primarily patients with a history of cardiovascular events.
• Safety concerns: bleeding risks deter off-label or broader use.
• Competition from established and newer drugs offers no significant clinical advantage.
• Merck's decision to scale back commercialization impacts product visibility and sales.

Financial and Investment Considerations

• Sales revenue remains limited and unpredictable.
• Additional development or expanded indications face considerable clinical and regulatory hurdles.
• Licensing deals or partnerships could mitigate investment risk but depend on deal terms.
• The drug’s patent expires in 2029, potentially opening generic competition in the following years.

Intellectual Property and Patent Timeline

• Patent protections: Expiring in 2029.
• No recent patent extensions filed.
• Future generic entry could reduce pricing power.

Regulatory Risks

• Further adverse safety findings could constrain usage.
• Regulatory agencies may require additional data for expanded indications.
• Evolving guidelines might deprioritize the drug in favor of other therapies.

Strategic Position and Future Outlook

• Best suited as a niche therapy for high-risk patients intolerant to other antiplatelets.
• Market growth unlikely unless new indications emerge.
• Future value depends on positioning within combination therapies and potential label updates.

Key Takeaways

• ZONTIVITY is a niche antiplatelet with limited market penetration since FDA approval in 2014.
• Challenges include safety concerns, competition, and limited indications.
• Sales peaked early, with subsequent decline following Merck’s reduced commercialization efforts.
• The product faces patent expiration risk and competitive market pressures.
• Investment requires reassessment of potential for niche market share expansion versus diminishing returns.

FAQs

1. What are the primary limitations hindering ZONTIVITY's market growth?
   Safety profile with bleeding risk, limited indication scope, and heavy competition from established antiplatelets.

2. Would expanding indications improve ZONTIVITY’s commercial prospects?
   Potentially, but requires significant clinical trials demonstrating safety and efficacy in broader populations, which are unlikely given current data and safety concerns.

3. How does ZONTIVITY compare to other antiplatelet agents?
   It provides additional platelet inhibition via PAR-1 blockade but has not proven superior efficacy or safety, limiting its clinical appeal.

4. What is the impact of patent expiration on ZONTIVITY?
   Patent expiration in 2029 could lead to generic entry, reducing pricing power and narrowing profitability.

5. Are there any ongoing development efforts for ZONTIVITY?
   No major publicly disclosed clinical trials or development programs are ongoing, suggesting that Merck and its partners have limited plans for the drug’s future.

Sources

[1] FDA Approval and Label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204322s000lbl.pdf
[2] Merck Financial Reports: https://investors.merck.com/financials/default.aspx
[3] Market Data on Antiplatelets: https://i3investor.com/blogs/HealthcareStocks/2021/04/05/Market_Dynamics_of_Antiplatelet_Drugs.jsp
[4] Clinical Trials - TRA 2°P-TIMI 50: https://www.nejm.org/doi/full/10.1056/NEJMoa1315436
[5] Patent Data: https://patents.google.com/patent/US8883357B2